Loading…
Based on limited metadata, BR SAS, a company involved with products categorized as "Other," received an FDA Warning Letter on June 8, 2018. Without access to the full letter text or a detailed subject line, the specific nature of the regulatory violations cannot be determined from the available information. The issuing office is not identified in the metadata provided, which limits clarity on the regulatory pathway or product category involved. To understand the full scope and details of the compliance concerns, the complete Warning Letter would need to be reviewed.